GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » Net Debt Paydown Yield %

Provention Bio (Provention Bio) Net Debt Paydown Yield % : 0.00% (As of Jun. 06, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Provention Bio Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Provention Bio's Net Debt Paydown Yield % was 0.00%.


Provention Bio Net Debt Paydown Yield % Historical Data

The historical data trend for Provention Bio's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio Net Debt Paydown Yield % Chart

Provention Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Debt Paydown Yield %
Get a 7-Day Free Trial - - - - -

Provention Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Provention Bio's Net Debt Paydown Yield %

For the Biotechnology subindustry, Provention Bio's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provention Bio's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provention Bio's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Provention Bio's Net Debt Paydown Yield % falls into.



Provention Bio Net Debt Paydown Yield % Calculation

Provention Bio's Net Debt Paydown Yield % for the quarter that ended in Dec. 2022 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 0.64-12.19 )/926.647589
=-1.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Provention Bio  (NAS:PRVB) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Provention Bio Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Provention Bio's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Provention Bio (Provention Bio) Business Description

Traded in Other Exchanges
N/A
Address
55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.
Executives
Sessa Capital (master), L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer director, 10 percent owner, officer: President and CEO PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon director, 10 percent owner, officer: Chief Scientific Officer C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel officer: Chief Accounting Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien officer: Chief People Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi officer: Chief Operations Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio officer: Chief Quality Officer ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos officer: Chief Medical Officer & COO ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche officer: Chief Financial Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701